Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The
official language of this press release is Japanese, and the Japanese version takes
precedence over the English version in terms of content and interpretation.

<Press Release>
November 20, 2023
Chordia Announces Completion of Patient Enrollment in the Phase 1 Study
for Solid Tumors and Hematologic Malignancies in Japan.
Kanagawa, Japan, November 20, 2023 – Chordia Therapeutics Inc. (Chordia) ispleased to announce the completion of patient enrollment in the Phase 1 clinical trialof CTX-712, a selective pan-CDC2-like kinase inhibitor, in patients with solid tumors
and hematologic malignancies in Japan. Through collaboration with universities,
research institutes, and companies in the healthcare industry, we will continue toresearch and develop anti-cancer drugs, with the aim of creating new, innovative drugs.
For more information, please refer to jRCT2080224127
Please visit: Japan Registry of Clinical Trials
About CTX-712
CTX-712 is a first-in-class, orally available, and selective small molecule inhibitor ofCDC2-like kinase (CLK), a key regulator of the RNA splicing process that plays animportant role in cell growth. CTX-712 inhibits the growth of various human tumor
cell lines in vitro, and in addition, exhibits antitumor activity in multiple xenograft
mouse models in vivo. In addition to the Phase 1 clinical trial in Japan, the Phase 1/2
clinical trial in the United States is ongoing. For more information on the Phase 1/2
clinical trial in the United States, please visit: clinicaltrials.gov/ (NCT05732103).
Important NoticeIn this press release, the definition of “press release” covers any oral presentation,question, and answer session, and written and/or oral materials discussed or distributedby Chordia Therapeutics in connection with this press release. This press release(including the oral description and related questions and answers) is not intended toconstitute, represent, or form part of any offer, invitation, or solicitation to purchase
and/or acquire anything, including securities.
Disclaimer
Any announcements by Chordia Therapeutics, including this press release, may
contain information on products derived from pharmaceutical developments, but areintended to inform the latest information related to Chordia’s business, and notintended as promotions, solicitations, advertisements, or to provide medical advice.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

Forward-Looking Statements
This press release and materials distributed in connection with this press release may
contain forward-looking statements, information, beliefs, and opinions concerning ourfuture operations, future positioning, and performance, including estimates,
projections, goals, and plans. Forward-looking statements may include, but are notlimited to, expressions such as "goals," "plans," "beliefs," "hopes," "continues,""expects," "intends," "assures," "will," "may," "should," "would," "could," "estimates,""projects," and/or other similar expressions, or the negative thereof. These forwardlooking statements are based on assumptions concerning a number of important factors,
including the following, which could cause actual results to differ materially fromthose expressed or implied by the forward-looking statements; highly influential
factors that include economic conditions surrounding our global business, which
include general economic conditions in Japan and the United States, competitive
pressures and developments including changes in applicable laws and regulations,which include global healthcare reform, uncertainty as to our clinical success, andchallenges inherent in new product development (which include regulatory decisions
and their timing,) uncertainty as to the commercial success of new and existingproducts manufacturing difficulties, delays fluctuations in interest rates and exchange
rates claims or concerns regarding the safety or efficacy of commercial products orproduct candidates the impact of a health crisis, such as the COVID-19 pandemic, onChordia and its customers and suppliers (including foreign governments in countries
in which the Company conducts business) or other aspects of its business. We
undertake no obligation to update any forward-looking statements contained in thispress release or any other forward-looking statements we may make, except as requiredby law or stock exchange rules. Past performance is not indicative of future operating
results, and any of our operating results or statements in this press release are notestimates, forecasts, warranties, or projections of our future operating results.
About Chordia Therapeutics
Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture,
Japan, engaged in the research and development of novel therapies for cancers.
Chordia’s lead asset CLK inhibitor CTX-712 is under Phase 1 clinical study in Japanand Phase1/2 clinical study in US. CTX-712 potentially targets the vulnerability ofcancer and is expected to deliver benefit to patients of various types of cancer. In
addition to CTX-712, Chordia is engaged in the research of several preclinical assets,
including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers
with specific abnormalities, as well as GCN2 inhibitors.
Established:
Address:
Representative:
Website:November 2017
26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Hiroshi Miyake, Representative Director
https://www.chordiatherapeutics.com/en/

For more information, contact IR, Mizobe: ir@chordiatherapeutics.com